View Older Stories
-
Form SCHEDULE 13G Helix Acquisition Corp. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Rezolute, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Ovid Therapeutics Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Camp4 Therapeutics Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Talkspace, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Rallybio Corp Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Nasus Pharma Ltd Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G TXNM ENERGY INC Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Korro Bio Ops, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Cellectar Biosciences raises up to $140 million in oversubscribed financing
-
Sagimet prices $175 million stock offering at $6 per share
-
Adlai Nortye raises $150 million in private placement financing
-
Galera and Obsidian merge in $350 million all-stock deal
-
Obsidian Therapeutics and Galera Therapeutics announce merger with $350M funding
-
American Integrity Insurance names Brian Foley as CFO
-
Ovid Therapeutics prices $60 million private placement for drug development
-
Korro Bio raises $85 million in oversubscribed private placement
-
Relmada Therapeutics raises $160 million in oversubscribed private placement
-
Sensei Biotherapeutics acquires Faeth Therapeutics for $200 million
-
Form SCHEDULE 13G Minerva Neurosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Contineum Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
LB Pharmaceuticals raises $100 million in private placement
-
Adlai Nortye raises $140 million in private placement financing
-
Crescent Biopharma raises $185 million, partners with Kelun-Biotech
-
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Spirit AeroSystems Holdi Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Arcturus Therapeutics Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Lottery.com Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Camping World Holdings, Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G/A Beyond Air, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
-
Opus Genetics advances LCA5 gene therapy toward pivotal trial after FDA meeting
-
Opus Genetics raises $23 million in registered direct offering
-
Tango Therapeutics raises $225 million in stock offering
-
Expedia Group names Rob Bevegni as VP of investor relations
-
Minerva Neurosciences secures up to $200 million for schizophrenia drug trial

